Allopurinol NDC 59651-285

NDC codes

FDA NDC Directory

Product NDC (as listed)59651-285Labeler and product segments. Claims need a package NDC.

Product NDC at billing width59651-0285Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
59651-285-01	59651028501	100 TABLET in 1 BOTTLE (59651-285-01)Marketed from Apr 14, 2025
59651-285-99	59651028599	1000 TABLET in 1 BOTTLE (59651-285-99)Marketed from Apr 14, 2025

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Allopurinol
Generic name (nonproprietary): allopurinol
Active ingredients: Allopurinol — 100 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Aurobindo Pharma Limited
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 215091
Marketing start: Apr 14, 2025
Listing expires: Dec 31, 2027
Other FDA classes: Xanthine Oxidase Inhibitors (Mechanism)
Identifiers: Product ID 59651-285_ef67cf70-5cf4-4b0d-86a5-c5af60228180SPL ID ef67cf70-5cf4-4b0d-86a5-c5af60228180SPL set ID 311ca755-c022-4251-97eb-dd9be86a993fRxCUI 197319, 197320UNII 63CZ7GJN5I
Pharmacologic class: Xanthine Oxidase Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N459651028501 followed by a unit qualifier and the quantity

Package 59651-0285-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Apr 17, 2026.

Indications (excerpt from the label)

Allopurinol tablets are indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management of adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels The management of adult patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes (such as reduction of dietary sodium, non-dairy animal protein, oxylate rich foods, refined sugars and i…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 215091

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 215091
Product	Strength	Form · route	Labeler	Product NDC
Allopurinol	Allopurinol 300 mg/1	TabletOral	PD-Rx Pharmaceuticals, Inc.	72789-593
Allopurinol	Allopurinol 300 mg/1	TabletOral	Aurobindo Pharma Limited	59651-286